<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ETF Trends &#187; Biotechnology</title>
	<atom:link href="http://www.etftrends.com/tag/biotechnology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.etftrends.com</link>
	<description>Setting the Pace for Exchange Traded Funds</description>
	<lastBuildDate>Sun, 12 Feb 2012 11:00:32 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Biotech ETFs Break Out</title>
		<link>http://www.etftrends.com/2012/01/biotech-etfs-break-out/</link>
		<comments>http://www.etftrends.com/2012/01/biotech-etfs-break-out/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 14:45:51 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=74303</guid>
		<description><![CDATA[The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector&#8217;s largest ETF posting a gain of 20% over the past three months.
The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up 9.6% year to date, compared with a 4.1% [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/01/biotech-etfs-break-out/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Six HOLDRS Become Van Eck ETFs</title>
		<link>http://www.etftrends.com/2011/12/six-holdrs-become-van-eck-etfs/</link>
		<comments>http://www.etftrends.com/2011/12/six-holdrs-become-van-eck-etfs/#comments</comments>
		<pubDate>Wed, 21 Dec 2011 12:16:48 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[New ETFs]]></category>
		<category><![CDATA[Banks]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[OIH]]></category>
		<category><![CDATA[Oil]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[RKH]]></category>
		<category><![CDATA[RTH]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Semiconductors]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[SMH]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=72136</guid>
		<description><![CDATA[Six Merrill Lynch HOLDRS exchange traded securities stopped trading as planned on Tuesday. The funds were officially transferred and changed into Van Eck Global exchange traded funds, and the new funds will begin trading Wednesday.
Trading in the biotech, banking, oil services, pharmaceuticals, retail and semiconductor HOLDRs halted on Tuesday, according to Van Eck. [HOLDRS Making [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/12/six-holdrs-become-van-eck-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Utilities, Consumer and Pharma ETFs Lead 2011</title>
		<link>http://www.etftrends.com/2011/12/utilities-consumer-and-pharma-etfs-lead-2011/</link>
		<comments>http://www.etftrends.com/2011/12/utilities-consumer-and-pharma-etfs-lead-2011/#comments</comments>
		<pubDate>Mon, 19 Dec 2011 12:31:29 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Consumer Staples]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[VDC]]></category>
		<category><![CDATA[XLP]]></category>
		<category><![CDATA[XLU]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=71788</guid>
		<description><![CDATA[Disruptions in the global economy have kept international equities suppressed, with a devastating Japanese earthquake crippling the normal supply chain between the Asia economies and escalating concerns over the Eurozone financial debt crisis. However, investors who opted to stick it out in domestic equity markets and exchange traded funds fared much better.
According to an S&#38;P [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/12/utilities-consumer-and-pharma-etfs-lead-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dividends, Safety Drive 2011 Sector ETF Winners</title>
		<link>http://www.etftrends.com/2011/12/dividends-safety-drive-2011-sector-etf-winners/</link>
		<comments>http://www.etftrends.com/2011/12/dividends-safety-drive-2011-sector-etf-winners/#comments</comments>
		<pubDate>Mon, 05 Dec 2011 15:27:57 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Consumer Staples]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[XLP]]></category>
		<category><![CDATA[XLU]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=71030</guid>
		<description><![CDATA[With less than a month left in 2011, the best performers in sector exchange traded funds this year track industries known for dividends and some insulation from economic cycles. They include ETFs tracking utilities, pharmaceuticals and biotechnology, and consumer staples.
Utilities Select Sector SPDR Fund (NYSEArca: XLU) is up 14.2% year to date while the S&#38;P [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/12/dividends-safety-drive-2011-sector-etf-winners/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HOLDRS Making Transition to Market Vector ETFs</title>
		<link>http://www.etftrends.com/2011/11/holdrs-making-transition-to-market-vector-etfs/</link>
		<comments>http://www.etftrends.com/2011/11/holdrs-making-transition-to-market-vector-etfs/#comments</comments>
		<pubDate>Wed, 23 Nov 2011 19:44:41 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[New ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[ETF 101]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[OIH]]></category>
		<category><![CDATA[Oil & Gas Exploration]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[RKH]]></category>
		<category><![CDATA[RTH]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Semiconductors]]></category>
		<category><![CDATA[SMH]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=70305</guid>
		<description><![CDATA[Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch reached an accord on six HOLDRs in August, and now, the transition from the Merrill Lynch HOLDRs to Market Vector exchange traded funds is underway.
An exchange offer for the HOLDRS commenced on Nov. 11 and will run till 11:00 am Eastern time on [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/11/holdrs-making-transition-to-market-vector-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETF Spotlight: Pharmaceuticals</title>
		<link>http://www.etftrends.com/2011/10/etf-spotlight-pharmaceuticals/</link>
		<comments>http://www.etftrends.com/2011/10/etf-spotlight-pharmaceuticals/#comments</comments>
		<pubDate>Thu, 13 Oct 2011 20:18:47 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[ETF Spotlight]]></category>
		<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[ETF 101]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XPH]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=66571</guid>
		<description><![CDATA[ETF spotlight on SPDR S&#38;P Pharmaceuticals ETF (NYSEArca: XPH), part of an ongoing series.
Assets: $241.21 million.
Objective: The SPDR S&#38;P Pharmaceuticals ETF tries to reflect the performance of the S&#38;P Pharmaceuticals Select Industry Index, which tracks U.S-listed companies engaged in the pharmaceuticals industry.
Holdings: Top holdings include: Salix Pharma Inc (NasdaqGS: SLXP) 4.57%, Bristol Myers Squibb Co. [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/10/etf-spotlight-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Van Eck, Merrill Lynch in Agreement Over HOLDRS</title>
		<link>http://www.etftrends.com/2011/08/van-eck-merrill-lynch-in-agreement-over-holdrs/</link>
		<comments>http://www.etftrends.com/2011/08/van-eck-merrill-lynch-in-agreement-over-holdrs/#comments</comments>
		<pubDate>Mon, 15 Aug 2011 12:26:15 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[New ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Energy]]></category>
		<category><![CDATA[ETF 101]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[OIH]]></category>
		<category><![CDATA[Oil]]></category>
		<category><![CDATA[Oil & Gas Exploration]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[RKH]]></category>
		<category><![CDATA[RTH]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Semiconductors]]></category>
		<category><![CDATA[SMH]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=60671</guid>
		<description><![CDATA[Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch have reached a deal in which Van Eck plans to offer investors in six HOLDRS the chance to swap for shares of new exchange traded funds.

Van Eck filed for six sector-specific ETFs with the Securities and Exchange Commission to issue the Merrill-Lynch HOLDRs [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/08/van-eck-merrill-lynch-in-agreement-over-holdrs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Mixed After Gilead Subpoena</title>
		<link>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/</link>
		<comments>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/#comments</comments>
		<pubDate>Mon, 13 Jun 2011 17:53:52 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=56144</guid>
		<description><![CDATA[Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice.
Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday said it has received a request for information from the U.S. Attorney&#8217;s Office for [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs: Orexigen Hit By Regulatory Hammer</title>
		<link>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/</link>
		<comments>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/#comments</comments>
		<pubDate>Fri, 03 Jun 2011 19:47:41 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=55162</guid>
		<description><![CDATA[Biotech sector and related exchange traded funds (ETFs) trade lower as one drug maker garners notoriety after regulatory hurdles puts a hold on the advancement of an anticipated diet pill.

iShares Nasdaq Biotechnology (NYSEArca: IBB) is down 0.83%.
First Trust Amex Biotech Index Fund (NYSEAca: FBT) is down 0.74%.
iShares Dow Jones U.S. Pharmaceutical Index Fund (NYSEArca: IHE) [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tom Lydon Discusses ETF Sector Rotation on Breakout</title>
		<link>http://www.etftrends.com/2011/05/tom-lydon-discusses-etf-sector-rotation-on-breakout/</link>
		<comments>http://www.etftrends.com/2011/05/tom-lydon-discusses-etf-sector-rotation-on-breakout/#comments</comments>
		<pubDate>Tue, 24 May 2011 15:45:53 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[ETF Trends in the Press]]></category>
		<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Airlines]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Consumer Staples]]></category>
		<category><![CDATA[EPU]]></category>
		<category><![CDATA[MOO]]></category>
		<category><![CDATA[Sector ETFs]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=54319</guid>
		<description><![CDATA[Tom Lydon appeared on Yahoo Finance&#8217;s Breakout on Tuesday morning to talk about sectors that are trending, such as biotech, consumer staples and more. Watch the Breakout video to see the full interview.
]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/05/tom-lydon-discusses-etf-sector-rotation-on-breakout/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Teva, Cephalon Boost Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/#comments</comments>
		<pubDate>Mon, 02 May 2011 15:45:58 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=52575</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) rallied to open the week after Teva Pharmaceutical (NasdaqGS: TEVA) said it’s buying Cephalon (NasdaqGS: CEPH) for $6.8 billion in a blockbuster sector deal.
The combined company would represent about $7 billion in annual sales. Shares of Teva and Cephalon were both up more than 3% in recent trading.
&#8220;This is transforming [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Earnings, Drug Data to Lift Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 12:55:22 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=51598</guid>
		<description><![CDATA[Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug.
The data on the drug, BG-12, was “very competitive versus other approved and pipeline MS therapies” and the results are “a significant catalyst for Biogen shares,” said [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs And A Global Approach Help Investors Access Biotech</title>
		<link>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/</link>
		<comments>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/#comments</comments>
		<pubDate>Fri, 11 Mar 2011 09:00:37 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=47499</guid>
		<description><![CDATA[Investing in biotech stocks and companies is so much like gambling, the risk is sometimes not worth it. Why not mitigate the risk and invest in an exchange traded fund (ETF) instead, which will give investors exposure to several companies at once.[Dissipate The Risk In Biotechnology With ETFs.]
According to MinyanVille, the process of New Drug [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Biotechnology ETFs to Play Innovation</title>
		<link>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/</link>
		<comments>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 22:00:10 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[HOLDRs]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46796</guid>
		<description><![CDATA[While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector.
Currently, the biotech industry is full of fast-growing and very profitable companies; however, [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs Turn Sunny Side Up on M&amp;A and Earnings</title>
		<link>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/</link>
		<comments>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 16:30:59 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[Industrial Metals]]></category>
		<category><![CDATA[NASDAQ]]></category>
		<category><![CDATA[PMR]]></category>
		<category><![CDATA[QTEC]]></category>
		<category><![CDATA[Real Estate]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[VPU]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46623</guid>
		<description><![CDATA[Reversing a few days of weak starts, exchange traded funds (ETFs) opened higher as investors respond to another round of earnings, corporate deal making and economic reports.

U.S. core producer prices in January rose to their highest rate in more than two years, hinting at a build-up in inflation pressures as the recovery gathers pace, a [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

